Lantern Pharma's LP-184 Receives Rare Pediatric, Orphan Drug Tags For Rare Form Of Cancer

The FDA has granted Rare Pediatric Disease and Orphan Drug Designations to Lantern Pharma Inc's LTRN LP-184 for Atypical Teratoid Rhabdoid Tumor (ATRT), a form of cancer of the Central Nervous System.

• LP-184 is a small molecule drug candidate and next-generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or harbor mutations in DNA repair pathways. 
• Related content: Benzinga's Full FDA Calendar.
• The FDA has previously granted LP-184 Orphan Drug status for pancreatic cancer and malignant glioma, including glioblastoma multiforme.
• Price Action: LTRN shares are up 11.1% at $6.80 during the premarket session on the last check Monday.